EUCTR2004-000120-32-IT进行中（未招募）不适用
Early glycoprotein IIb/IIIa inhibition in non-ST-segment elevation acute coronary syndrome a randomized, placebo-controlled trial evaluating the clinica benefits of early front-loated Eptifibatide in the treatment of patients with non-ST-segment elevation acute coronary syndrome EARLY ACS
SCHERING-PLOUGH0 个研究点目标入组 10,500 人开始时间: 2007年2月2日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 10,500
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
不适用
Early Glycoprotein IIb/IIIa Inhibition in Non-ST-segment Elevation Acute Coronary Syndrome: A Randomized, Placebo-Controlled Trial Evaluating the Clinical Benefits of Early Front-loaded Eptifibatide in the Treatment of Patients with Non-ST-segment Elevation Acute Coronary Syndrome(EARLY ACS) - EARLY ACSPatients who present with high-risk non-ST-segment elevation acute coronary syndrome who are planned to undergo an invasive strategy no sooner than the next calendar day following randomization.MedDRA version: 6.0Level: PTClassification code 10051592EUCTR2004-000120-32-DKSchering-Plough A/S10,500
进行中（未招募）
不适用
Early Glycoprotein IIb/IIIa Inhibition in Non-ST-segment Elevation Acute Coronary Syndrome: A Randomized, Placebo-Controlled Trial Evaluating the Clinical Benefits of Early Front-loaded Eptifibatide in the Treatment of Patients with Non-ST-segment Elevation Acute Coronary Syndrome(EARLY ACS) - EARLY ACSPatients who present with high-risk non-ST-segment elevation acute coronary syndrome who are planned to undergo an invasive strategy no sooner than the next calendar day following randomization.MedDRA version: 9.1Level: LLTClassification code 10051592Term: Acute coronary syndromeEUCTR2004-000120-32-CZSchering-Plough Research Institute9,500
进行中（未招募）
1 期
Early Glycoprotein IIb/IIIa Inhibition in Non-ST-segment Elevation Acute Coronary Syndrome: A Randomized, Placebo-Controlled Trial Evaluating the Clinical Benefits of Early Front-loaded Eptifibatide in the Treatment of Patients with Non-ST-segment Elevation Acute Coronary Syndrome (EARLY ACS) - EARLY ACSPatients who present with high-risk non-ST-segment elevation acute coronary syndrome who are planned to undergo an invasive strategy no sooner than the next calendar day following randomization.MedDRA version: 6.0 Level: PT Classification code 10051592EUCTR2004-000120-32-GBSchering-Plough Research Institute10,500
进行中（未招募）
不适用
Early Glycoprotein IIb/IIIa Inhibition in Non-ST-segment Elevation Acute Coronary Syndrome: A Randomized, Placebo-Controlled Trial Evaluating the Clinical Benefits of Early Front-loaded Eptifibatide in the Treatment of Patients with Non-ST-segment Elevation Acute Coronary Syndrome(EARLY ACS) - EARLY ACSEUCTR2004-000120-32-HUSchering-Plough Research Institute10,500
进行中（未招募）
不适用
Early Glycoprotein IIb/IIIa Inhibition in Non-ST-segment Elevation Acute Coronary Syndrome: A Randomized, Placebo-Controlled Trial Evaluating the Clinical Benefits of Early Front-loaded Eptifibatide in the Treatment of Patients with Non-ST-segment Elevation Acute Coronary Syndrome(EARLY ACS) - EARLY ACSPatients who present with high-risk non-ST-segment elevation acute coronary syndrome who are planned to undergo an invasive strategy no sooner than the next calendar day following randomization.MedDRA version: 6.0Level: PTClassification code 10051592EUCTR2004-000120-32-ATSchering-Plough Research Institute10,500